[go: up one dir, main page]

ECSP13012665A - Nueva forma de administracion de inhibidor de encefalinasa - Google Patents

Nueva forma de administracion de inhibidor de encefalinasa

Info

Publication number
ECSP13012665A
ECSP13012665A ECSP13012665A ECSP13012665A EC SP13012665 A ECSP13012665 A EC SP13012665A EC SP13012665 A ECSP13012665 A EC SP13012665A EC SP13012665 A ECSP13012665 A EC SP13012665A
Authority
EC
Ecuador
Prior art keywords
new
encephalinasa
administration form
inhibitor administration
inhibitor
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Xavier Ligneau
Jean Stéphane JULIEN
Marc Maury
Philippe Robert
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of ECSP13012665A publication Critical patent/ECSP13012665A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con una nueva formulación de un inhibidor de encefalinasa, tal como racecadotril o dexecadotril, con el proceso para la preparación del mismo y con el uso del mismo en el tratamiento de diarrea.
ECSP13012665 2010-12-10 2013-06-06 Nueva forma de administracion de inhibidor de encefalinasa ECSP13012665A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306397A EP2462922A1 (en) 2010-12-10 2010-12-10 New form of administration of enkephalinase inhibitor

Publications (1)

Publication Number Publication Date
ECSP13012665A true ECSP13012665A (es) 2013-08-30

Family

ID=45092498

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012665 ECSP13012665A (es) 2010-12-10 2013-06-06 Nueva forma de administracion de inhibidor de encefalinasa

Country Status (32)

Country Link
US (1) US9439853B2 (es)
EP (2) EP2462922A1 (es)
JP (1) JP5847192B2 (es)
KR (1) KR101837685B1 (es)
CN (1) CN103338749B (es)
AP (1) AP3787A (es)
AU (1) AU2011340500B2 (es)
BR (1) BR112013014388A2 (es)
CA (1) CA2820835C (es)
CO (1) CO6731092A2 (es)
CY (1) CY1123056T1 (es)
DK (1) DK2648696T3 (es)
EA (1) EA022730B1 (es)
EC (1) ECSP13012665A (es)
ES (1) ES2791710T3 (es)
HR (1) HRP20200555T1 (es)
HU (1) HUE049273T2 (es)
IL (1) IL226775A (es)
LT (1) LT2648696T (es)
MA (1) MA34724B1 (es)
ME (1) ME03769B (es)
MX (1) MX354858B (es)
NZ (1) NZ611597A (es)
PL (1) PL2648696T3 (es)
PT (1) PT2648696T (es)
RS (1) RS60197B1 (es)
SG (1) SG191068A1 (es)
SI (1) SI2648696T1 (es)
SM (1) SMT202000229T1 (es)
TN (1) TN2013000239A1 (es)
UA (1) UA111835C2 (es)
WO (1) WO2012076691A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
EP2866789B1 (en) * 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Racecadotril lipid compositions
EP2866802B1 (en) * 2012-06-28 2016-07-27 Johnson & Johnson Consumer Inc. Racecadotril liquid compositions
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions
ES2549127T1 (es) 2014-03-10 2015-10-23 Galenicum Health S.L. Composiciones farmacéuticas que comprenden un principio activo
EP2949318A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising racecadotril
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
CN105125477A (zh) * 2015-08-19 2015-12-09 黑龙江佰彤儿童药物研究有限公司 一种含消旋卡多曲的药物制剂及制备方法
IT201700099690A1 (it) * 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
CZ299591B6 (cs) 2000-06-23 2008-09-10 Bioprojet Suchý práškový farmaceutický prostredek pro orální podání
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
UA80682C2 (en) 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
EP1563848A1 (en) * 2004-02-12 2005-08-17 Bioprojet New combinations of an anti-emetic agent and an enkephalinase inhibitor
WO2007102171A2 (en) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
CN101103960B (zh) * 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
TW201014830A (en) 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Also Published As

Publication number Publication date
HUE049273T2 (hu) 2020-09-28
ES2791710T3 (es) 2020-11-05
CY1123056T1 (el) 2021-10-29
WO2012076691A1 (en) 2012-06-14
AP2013006971A0 (en) 2013-07-31
UA111835C2 (uk) 2016-06-24
PT2648696T (pt) 2020-05-13
SG191068A1 (en) 2013-07-31
CA2820835C (en) 2019-01-08
JP2014503512A (ja) 2014-02-13
IL226775A (en) 2017-09-28
RS60197B1 (sr) 2020-06-30
US20130331423A1 (en) 2013-12-12
MA34724B1 (fr) 2013-12-03
ME03769B (me) 2021-04-20
AU2011340500A1 (en) 2013-06-27
EP2648696A1 (en) 2013-10-16
EP2462922A1 (en) 2012-06-13
EP2648696B1 (en) 2020-02-19
CN103338749A (zh) 2013-10-02
PL2648696T3 (pl) 2020-07-27
EA022730B1 (ru) 2016-02-29
CO6731092A2 (es) 2013-08-15
MX2013006492A (es) 2013-11-01
AP3787A (en) 2016-08-31
BR112013014388A2 (pt) 2016-09-27
KR20130124335A (ko) 2013-11-13
SI2648696T1 (sl) 2020-07-31
LT2648696T (lt) 2020-05-11
EA201300688A1 (ru) 2014-11-28
KR101837685B1 (ko) 2018-03-12
TN2013000239A1 (en) 2014-11-10
NZ611597A (en) 2015-01-30
HRP20200555T1 (hr) 2020-07-24
US9439853B2 (en) 2016-09-13
MX354858B (es) 2018-03-23
JP5847192B2 (ja) 2016-01-20
DK2648696T3 (da) 2020-05-04
CN103338749B (zh) 2017-04-26
SMT202000229T1 (it) 2020-07-08
AU2011340500B2 (en) 2016-10-20
CA2820835A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
CO6731092A2 (es) Nueva forma de administración de inhibidor de encefalinasa
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
MX394441B (es) Una formulación a base de besifloxacina para usarse en el tratamiento del acné resistente a fármacos
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
MX2015016406A (es) Formulacion de revestimiento para madera.
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
MX2017006149A (es) Composiciones para el cuidado personal con dos fases beneficas.
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
GT201500247A (es) Imidazopiridazinas sustituidas
CR20150211A (es) Compuestos diméricos
PH12014502860A1 (en) Racecadotril liquid compositions
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
CO7141434A2 (es) Nueva forma de dosificación formulación de abediterol
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer